Pde-4 inhibition rescues aberrant synaptic plasticity in drosophila and mouse models of fragile x syndrome

Journal of Neuroscience

Volumn 35, Issue 1, 2015, Pages 396-408

  Choi, Catherine H ^a,b,c   Schoenfeld, Brian P ^a,d   Weisz, Eliana D ^d   Bell, Aaron J ^a,d   Chambers, Daniel B ^e   Hinchey, Joseph ^a   Choi, Richard J ^a   Hinchey, Paul ^a   Kollaros, Maria ^a   Gertner, Michael J ^a   Ferrick, Neal J ^a,d   Terlizzi, Allison M ^a   Yohn, Nicole ^d   Koenigsberg, Eric ^a   Liebelt, David A ^a   Zukin, R Suzanne ^a   Woo, Newton H ^f   Tranfaglia, Michael R ^g   Louneva, Natalia ^d   Arnold, Steven E ^d   Siegel, Steven J ^d   Bolduc, Francois V ^e   McDonald, Thomas V ^a   Jongens, Thomas A ^d   McBride, Sean M J ^a,d   more..

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Valley Health   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g FRAXA Research Foundation   (United States)

Author keywords

CAMP; Drosophila; Fragile X; Memory; Mouse; Phosphodiesterase 4

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 3, 5 DIHYDROXYPHENYLGLYCINE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIMETHYL SULFOXIDE; METABOTROPIC RECEPTOR ANTAGONIST; PHOSPHODIESTERASE IV; ROLIPRAM; UNCLASSIFIED DRUG; PHOSPHODIESTERASE IV INHIBITOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; COGNITION; CONTROLLED STUDY; DROSOPHILA; DRUG MEGADOSE; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRAGILE X SYNDROME; GENE MUTATION; GENETIC TRANSCRIPTION; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; LEARNING; MALE; MOUSE; MUTANT MOUSE STRAIN; NERVE CELL PLASTICITY; NERVE STIMULATION; NONHUMAN; OLFACTORY DISCRIMINATION; OLFACTORY MEMORY; PROTEIN PHOSPHORYLATION; RECALL; SHOCK; SHORT TERM MEMORY; SIGNAL TRANSDUCTION; SMELLING; STIMULUS RESPONSE; SYNAPTIC TRANSMISSION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DISEASE MODELS, ANIMAL; DROSOPHILA; FEMALE; FRAGILE X SYNDROME; MALE; MICE; MICE, KNOCKOUT; NEURONAL PLASTICITY; PHOSPHODIESTERASE 4 INHIBITORS;

EID: 84920546031     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1356-12.2015     Document Type: Article

References (91)

1. Akins MR, Berk-Rauch HE, Fallon JR (2009) Presynaptic translation: stepping outofthe postsynaptic shadow. Front Neural Circuits 3:17.
2. Bailey CP, Nicholls RE, Zhang XL, Zhou ZY, Müller W, Kandel ER, Stanton PK (2008) Galpha(i2) inhibition of adenylate cyclase regulates presyn-aptic activity and unmasks cGMP-dependent long-term depression at Schaffer collateral-CA1 hippocampal synapses. Learn Mem 15:261–270.
3. Banerjee P, Schoenfeld BP, Bell AJ, Choi CH, Bradley MP, Hinchey P, Kolla-ros M, Park JH, McBride SM, Dockendorff TC (2010) Short- and long-term memory are modulated by multiple isoforms of the fragile X mental retardation protein. J Neurosci 30:6782–6792.
4. Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E (1998) Rolip-ram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci U S A 95:15020–15025.
5. Bear MF, Huber KM, Warren ST (2004) The mGluR theory of fragile X mental retardation. Trends Neurosci 27:370–377.
6. Berry-Kravis E, Ciurlionis R (1998) Overexpression of fragile X gene (FMR-1) transcripts increases cAMP production in neural cells. J Neuro-sci Res 51:41–48.
7. Berry-Kravis E, Hicar M, Ciurlionis R (1995) Reduced cyclic AMP production in fragile X syndrome: cytogenetic and molecular correlations. Pedi-atr Res 38:638–643.
8. Berry-Kravis E, Huttenlocher PR (1992) Cyclic AMP metabolism in fragile X syndrome. Ann Neurol 31:22–26.
9. Berry-Kravis E, Sklena P (1993) Demonstration of abnormal cyclic AMP production in platelets from patients with fragile X syndrome. Am J Med Genet 45:81–87.
10. Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, Weiler IJ, Greenough WT (2008) Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr 29:293-302.
11. Bhogal B, Jongens TA (2010) Fragile X syndrome and model organisms: identifying potential routes of therapeutic intervention. Dis Model Mech 3:693–700.
12. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM (2009) Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 46:94–102.
13. Bolduc FV, Bell K, Cox H, Broadie KS, Tully T (2008) Excess protein synthesis in Drosophila fragile X mutants impairs long-term memory. Nat Neurosci 11:1143–1145.
14. Bolduc FV, Tully T (2009) Fruit flies and intellectual disability. Fly (Austin) 3:91–104.
15. Buescher AV, Cidav Z, Knapp M, Mandell DS (2014) Costs of autism spectrum disorders in the United Kingdom and the United States. JAMA Pediatr 168:721–728.
16. Byers D, Davis RL, Kiger JA Jr (1981) Defect in cyclic AMP phosphodiesterase due to the dunce mutation of learning in Drosophila melanogaster. Nature 289:79–81.
17. Choi CH, McBride SM, Schoenfeld BP, Liebelt DA, Ferreiro D, Ferrick NJ, Hinchey P, Kollaros M, Rudominer RL, Terlizzi AM, Koenigsberg E, Wang Y, Sumida A, Nguyen HT, Bell AJ, McDonald TV, Jongens TA (2010) Age-dependent cognitive impairment in a Drosophila fragile X model and its pharmacological rescue. Biogerontology 11:347–362.
18. Choi CH, Schoenfeld BP, Bell AJ, Hinchey P, Kollaros M, Gertner MJ, Woo NH, Tranfaglia MR, Bear MF, Zukin RS, McDonald TV, Jongens TA, McBride SM (2011) Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment. Brain Res 1380:106–119.
19. Choi Y, Kim HS, Shin KY, Kim EM, Kim M, Kim HS, Park CH, Jeong YH, Yoo J, Lee JP, Chang KA, Kim S, Suh YH (2007) Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer’s disease models. Neuropsychopharmacology 32:2393–2404.
20. Cuello AC, Ferretti MT, Leon WC, Iulita MF, Melis T, Ducatenzeiler A, Bruno MA, Canneva F (2010) Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegener Dis 7:96–98.
21. Darnell JC, Klann E (2013) The translation of translational control by FMRP: therapeutic targets for FXS. Nat Neurosci 16:1530–1536.
22. Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, Stone EF, Chen C, Fak JJ, Chi SW, Licatalosi DD, Richter JD, Darnell RB (2011) FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146:247–261.
23. Davis RL (1993) Mushroom bodies and Drosophila learning. Neuron 11:1–14.
24. Davis RL, Kiger JA Jr (1981) Dunce mutants of Drosophila melanogaster: mutants defective in the cyclic AMP phosphodiesterase enzyme system. J Cell Biol 90:101–107.
25. Davis RL, Takayasu H, Eberwine M, Myres J (1989) Cloning and characterization of mammalian homologs of the Drosophila dunce + gene. Proc Natl Acad Sci USA 86:3604–3608.
26. Dockendorff TC, Su HS, McBride SM, Yang Z, Choi CH, Siwicki KK, Sehgal A, Jongens TA (2002) Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron 34:973-984.
27. Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF (2007) Correction of fragile X syndrome in mice. Neuron 56:955–962.
28. Dudai Y, Jan YN, Byers D, Quinn WG, Benzer S (1976) dunce, a mutant of Drosophila deficient in learning. Proc Natl Acad Sci U S A 73:1684–1688.
29. Duerr JS, Quinn WG (1982) ThreeDrosophila mutations that block associative learning also affect habituation and sensitization. Proc Natl Acad Sci U S A 79:3646–3650.
30. Dujardin F (1850) Memoire sur lesysteme nerveux des insectes. Ann Sci Nat Zool 14.
31. Fang X, Yu SX, Lu Y, Bast RC Jr, Woodgett JR, Mills GB (2000) Phosphor-ylation and inactivationof glycogen synthase kinase3 byprotein kinase A. Proc Natl Acad Sci U S A 97:11960–11965.
32. Franklin AV, King MK, Palomo V, Martinez A, McMahon LL, Jope RS (2014) Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice. Biol Psychiatry 75: 198–206.
33. Garcia-Alloza M, Prada C, Lattarulo C, Fine S, Borrelli LA, Betensky R, Greenberg SM, Frosch MP, Bacskai BJ (2009) Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy invivointransgenic mice.J Neurochem 109:1636–1647.
34. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 114:1624–1634.
35. Gross C, Berry-Kravis EM, Bassell GJ (2012) Therapeutic strategiesinfragile X syndrome: dysregulated mGluR signaling and beyond. Neuropsychop-harmacology 37:178–195.
36. Hagerman PJ (2008) The fragile X prevalence paradox. J Med Genet 45: 498–499.
37. Hagerman R, Lauterborn J, Au J, Berry-Kravis E (2012) Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ 54:297–335.
38. Henkel-Tigges J, Davis RL (1990) Rat homologs of the Drosophila dunce gene code for cyclic AMP phosphodiesterases sensitive to rolipram and RO 20–1724. Mol Pharmacol 37:7–10.
39. Hou J, Kuromi H, Fukasawa Y, Ueno K, Sakai T, Kidokoro Y (2004) Repetitive exposures to nicotine induce a hyper-responsiveness via the cAMP/ PKA/CREB signal pathway in Drosophila. J Neurobiol 60:249–261.
40. Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E (2006) Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron 51: 441–454.
41. Huber KM, Gallagher SM, Warren ST, Bear MF (2002) Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A 99:7746–7750.
42. Huber KM, Kayser MS, Bear MF (2000) Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science 288:1254–1257.
43. Huber KM, Roder JC, Bear MF (2001) Chemical induction of mGluR5- and protein synthesis-dependent long-term depression in hippocampal area CA1. J Neurophysiol 86:321–325.
44. Hwu WL, Wang TR, Lee YM (1997) FMR1 enhancer is regulated by cAMP through a cAMP-responsive element. DNA Cell Biol 16:449–453.
45. Impey S, McCorkle SR, Cha-Molstad H, Dwyer JM, Yochum GS, Boss JM, McWeeney S, Dunn JJ, Mandel G, Goodman RH (2004) Defining the CREB regulon: a genome-wide analysis of transcription factor regulatory regions. Cell 119:1041–1054.
46. Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA (2007) Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol 6:45–55.
47. Joiner MIA, Griffith LC (1997) CaM kinase II and visual input modulate memory formation in the neuronal circuit controlling courtship conditioning. J Neurosci 17:9384–9391.
48. Kamyshev NG, Iliadi KG, Bragina JV (1999) Drosophila conditioned courtship: two ways of testing memory. Learn Mem 6:1–20.
49. Kandel ER (2001) The molecular biology of memory storage: a dialogue between genes and synapses. Science 294:1030–1038.
50. Kane NS, Robichon A, Dickinson JA, Greenspan RJ (1997) Learning without performance in PKC-deficient Drosophila. Neuron 18:307–314.
51. Kanellopoulos AK, Semelidou O, Kotini AG, Anezaki M, Skoulakis EM (2012) Learning and memory deficits consequent to reduction of the fragile X mental retardation protein result from metabotropic glutamate receptor-mediated inhibitionofcAMP signaling in Drosophila. J Neurosci 32:13111–13124.
52. Keleman K, Krüttner S, Alenius M, Dickson BJ (2007) Function of the Dro-sophila CPEB protein Orb2 in long-term courtship memory. Nat Neuro-sci 10:1587–1593.
53. Kelleher RJ 3rd, Govindarajan A, Tonegawa S (2004) Translational regulatory mechanisms in persistent forms of synaptic plasticity. Neuron 44:59–73.
54. Kelley DJ, Davidson RJ, Elliott JL, Lahvis GP, Yin JC, Bhattacharyya A (2007) The cyclic AMP cascade is altered in the fragile X nervous system. PLoS One 2:e931.
55. Krueger DD, Bear MF (2011) Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med 62:411–429.
56. Li M, Wang X, Meintzer MK, Laessig T, Birnbaum MJ, Heidenreich KA (2000) Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta. Mol Cell Biol 20:9356–9363.
57. Li W, Cui Y, Kushner SA, Brown RA, Jentsch JD, Frankland PW, Cannon TD, Silva AJ (2005) The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits inamouse modelof neurofibromatosis type 1. Curr Biol 15:1961–1967.
58. Liu ZH, Chuang DM, Smith CB (2011) Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int J Neuropsychophar-macol 14:618–630.
59. Malenka RC, Bear MF (2004) LTP and LTD: an embarrassment of riches. Neuron 44:5–21.
60. Martin-Chouly CA, Astier A, Jacob C, Pruniaux MP, Bertrand C, Lagente V (2004) Modulation of matrix metalloproteinase production from hu man lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci 75: 823–840.
61. McBride SM, Giuliani G, Choi C, Krause P, Correale D, Watson K, Baker G, Siwicki KK (1999) Mushroom body ablation impairs short-term memory and long-term memory ofcourtship conditioning inDrosophila mela-nogaster. Neuron 24:967–977.
62. McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, Ferreiro D, Sehgal A, Siwicki KK, Dockendorff TC, Nguyen HT, McDonald TV, Jongens TA (2005) Pharmacological rescueof synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila modelof fragile Xsyndrome. Neuron 45:753–764.
63. McBride SM, Choi CH, Schoenfeld BP, Bell AJ, Liebelt DA, Ferreiro D, Choi RJ, Hinchey P, Kollaros M, Terlizzi AM, Ferrick NJ, Koenigsberg E, Ru-dominer RL, Sumida A, Chiorean S, Siwicki KK, Nguyen HT, Fortini ME, McDonald TV, Jongens TA (2010) Pharmacological and genetic rever-salofage-dependent cognitive deficits attributabletodecreased presenilin function. J Neurosci 30:9510–9522.
64. McBride SM, Bell AJ, Jongens TA (2012) Behavior in a Drosophila model of fragile X. Results Probl Cell Differ 54:83–117.
65. Michel CI, Kraft R, Restifo LL (2004) Defective neuronal development in the mushroom bodies of Drosophila fragile X mental retardation 1 mutants. J Neurosci 24:5798–5809.
66. Min WW, Yuskaitis CJ, Yan Q, Sikorski C, Chen S, Jope RS, Bauchwitz RP (2009) Elevated glycogen synthase kinase-3 activity inFragile Xmice: key metabolic regulator with evidence for treatment potential. Neurophar-macology 56:463–472.
67. Mines MA, Jope RS (2011) Glycogen synthase kinase-3: a promising therapeutic target for fragile X syndrome. Front Mol Neurosci 4:35.
68. Mines MA, Yuskaitis CJ, King MK, Beurel E, Jope RS (2010) GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS One 5:e9706.
69. Morales J, Hiesinger PR, Schroeder AJ, Kume K, Verstreken P, Jackson FR, Nelson DL, Hassan BA (2002) Drosophila fragile X protein, DFXR, regulates neuronal morphology and function in the brain. Neuron 34:961– 972.
70. Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH (2009) Minocycline reduces the development of abnormal tau species in models of Alzheimer’s disease. FASEB J 23:739–750.
71. Nosyreva ED, Huber KM (2006) Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J Neurophysiol 95:3291–3295.
72. O’Kane CJ (2011) Drosophila as a model organism for the study of neuro-psychiatric disorders. Curr Top Behav Neurosci 7:37–60.
73. Oger S, Méhats C, Dallot E, Cabrol D, Leroy MJ (2005) Evidence for a role of phosphodiesterase 4 in lipopolysaccharide-stimulated prostaglandin E2 production and matrix metalloproteinase-9 activity inhuman amniocho-rionic membranes. J Immunol 174:8082–8089.
74. Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, Ethell DW (2010) Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 10:91.
75. Pascual A, Préat T (2001) Localization of long-term memory within the Drosophila mushroom body. Science 294:1115–1117.
76. Raymond FL, Tarpey P (2006) The genetics of mental retardation. Hum Mol Genet 15:R110–R116.
77. Sánchez AJ, Puerta C, Ballester S, González P, Arriaga A, García-Merino A (2005) Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. J Neuroimmunol 168:13–20.
78. Santschi LA, Zhang XL, Stanton PK (2006) Activation of receptors negatively coupled to adenylate cyclase is required for induction of long-term synaptic depression at Schaffer collateral-CA1 synapses. J Neurobiol 66: 205–219.
79. Sato T, Tanaka K, Ohnishi Y, Teramoto T, Irifune M, Nishikawa T (2004) Inhibitory effects of group II mGluR-related drugs on memory performance in mice. Physiol Behav 80:747–758.
80. Siegel RW, Hall JC (1979) Conditioned responses in courtship behavior of normal and mutant Drosophila. Proc Natl Acad Sci U S A 76:3430–3434.
81. Skoulakis EM, Grammenoudi S (2006) Dunces and da Vincis: the genetics of learning and memory in Drosophila. Cell Mol Life Sci 63:975–988.
82. Tanji C, Yamamoto H, Yorioka N, Kohno N, Kikuchi K, Kikuchi A (2002) A-kinase anchoring protein AKAP220 binds to glycogen synthase kinase-3beta (GSK-3beta) and mediates protein kinase A-dependent inhibition of GSK-3beta. J Biol Chem 277:36955–36961.
83. Tessier CR, Broadie K (2012) Molecular and genetic analysisofthe Drosoph-ila model of fragile X syndrome. Results Probl Cell Differ 54:119–156.
84. Tully T, Quinn WG (1985) Classical conditioning and retention in normal and mutant Drosophila melanogaster. J Comp Physiol A Neuroethol Sens Neural Behav Physiol 157:263–277.
85. Walsh CA, Morrow EM, Rubenstein JL (2008) Autism and brain development. Cell 135:396–400.
86. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP (2005) Suppressionof two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49:1053–1066.
87. Yin JC, Del Vecchio M, Zhou H, Tully T (1995) CREB as a memory modulator: induced expression of a dCREB2 activator isoform enhances long-term memory in Drosophila. Cell 81:107–115.
88. Yuskaitis CJ, Beurel E, Jope RS (2010a) Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome. Biochim Biophys Acta 1802:1006–1012.
89. Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, Jope RS (2010b) Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol 79:632–646.
90. Zars T, Fischer M, Schulz R, Heisenberg M (2000) Localization of a short-term memory in Drosophila. Science 288:672–675.
91. Zhang YQ, Bailey AM, Matthies HJ, Renden RB, Smith MA, Speese SD, Rubin GM, Broadie K (2001) Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell 107:591–603.